TPIDB > 臨床試驗主持人
臨床試驗主持人
更新時間：2023-09-19
王金洲WANG, CHIN-CHOU
- 計畫主持人
- 執行臨床試驗年資 17 年 9 個月
-
ccwang52@cgmh.org.tw
發表文獻
33筆
31
Hsu PC, Lee SH, Chiu LC, Lee CS, Wu CE, Kuo SC, et al. Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan. Target Oncol. 2023.
32
Kuo CS, Tung PH, Huang AC, Wang CC, Chang JW, Liu CY, et al. A retrospective study of alectinib versus ceritinib in patients with advanced non-small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed. BMC Cancer. 2021;21(1):309.
33
Ko HW, Shie SS, Wang CW, Chiu CT, Wang CL, Yang TY, et al. Association of smoking status with non-small cell lung cancer patients harboring uncommon epidermal growth factor receptor mutation. Front Immunol. 2022;13:1011092.
